The University of Oxford and ReciBioPharm, Recipharm’s advanced biologics division and a CDMO, report that they are expanding their long-standing collaboration with the development of two blood-stage malaria vaccine candidates for Phase I/II clinical trials.
Since 2016, this collaboration has delivered five vaccine candidates and will now progress the manufacture of R78C and RH5.1 for the University’s Draper Lab, based in the department of pediatrics.
ReciBioPharm initially produced both the drug substance and drug product for R78C and is now handling large-scale fill and finish to meet increased vial demand for ongoing trials. Additionally, RH5.1, previously manufactured by another CDMO, is now being fully produced by ReciBiopharm, including drug substance, drug product, and large-scale fill and finish.
“This collaboration with ReciBioPharm has been instrumental in accelerating the development of our malaria vaccine portfolio,” said Simon Draper, DPhil, professor of vaccinology and translational medicine at the University of Oxford, and group leader of the Draper Lab. “With numerous malaria vaccine candidates now developed or in active development, this partnership plays a critical role in advancing innovative solutions aimed at reducing the global burden of malaria and supports our shared mission to eradicate malaria altogether.”
“Our ability to deliver drug substance and drug product for larger scales under GMP conditions makes us a strong partner for accelerating vaccine candidates from lab to clinic,” added Greg Behar, CEO of Recipharm.
Globally, malaria continues to pose a significant health threat. According to the World Health Organization’s World Malaria Report 2023, there were an estimated 249 million cases of malaria worldwide in 2022, resulting in 608,000 deaths. Notably, children under five accounted for 76% of all malaria deaths in the WHO African Region.
The post University of Oxford and ReciBioPharm Expand Malaria Vaccine Collaboration appeared first on GEN - Genetic Engineering and Biotechnology News.
Since 2016, this collaboration has delivered five vaccine candidates and will now progress the manufacture of R78C and RH5.1 for the University’s Draper Lab, based in the department of pediatrics.
ReciBioPharm initially produced both the drug substance and drug product for R78C and is now handling large-scale fill and finish to meet increased vial demand for ongoing trials. Additionally, RH5.1, previously manufactured by another CDMO, is now being fully produced by ReciBiopharm, including drug substance, drug product, and large-scale fill and finish.
“This collaboration with ReciBioPharm has been instrumental in accelerating the development of our malaria vaccine portfolio,” said Simon Draper, DPhil, professor of vaccinology and translational medicine at the University of Oxford, and group leader of the Draper Lab. “With numerous malaria vaccine candidates now developed or in active development, this partnership plays a critical role in advancing innovative solutions aimed at reducing the global burden of malaria and supports our shared mission to eradicate malaria altogether.”
“Our ability to deliver drug substance and drug product for larger scales under GMP conditions makes us a strong partner for accelerating vaccine candidates from lab to clinic,” added Greg Behar, CEO of Recipharm.
Globally, malaria continues to pose a significant health threat. According to the World Health Organization’s World Malaria Report 2023, there were an estimated 249 million cases of malaria worldwide in 2022, resulting in 608,000 deaths. Notably, children under five accounted for 76% of all malaria deaths in the WHO African Region.
The post University of Oxford and ReciBioPharm Expand Malaria Vaccine Collaboration appeared first on GEN - Genetic Engineering and Biotechnology News.